Given human immunodeficiency virus‐1 (HIV‐1)‐infected patients have alterations in the type I interferon (IFN‐I) pathway and are also at elevated risk of atherosclerosis, we evaluated IFN‐I response and subclinical cardiovascular disease (CVD) association in HIV‐1‐infected patients. Transcript levels of IFN‐α/β and IFN‐stimulated gene 56 (ISG56) were evaluated by RT/real‐time PCR in peripheral blood mononuclear cells collected from asymptomatic HIV‐1‐positive male patients at high risk of developing CVD (n = 34) and healthy subjects (n = 21). Stenosis degree (≥ or <50%), calcium volume score, calcium Agatston score, and myocardial extracellular volume were examined by coronary computerized tomography scan. Carotid intima‐media thickness (cIMT), Framingham risk score, atherosclerotic cardiovascular disease (ASCVD) score, and risk score developed by data collection on adverse effects of anti‐HIV drugs (D:A:D) were also measured. Increased IFN‐α, IFN‐β, and ISG56 levels were observed in all HIV‐1‐infected males compared to healthy controls (p < .001 for all genes analyzed). HIV‐1‐infected patients with a stenosis degree ≥50% showed a higher Framingham risk score (p = .019), which was correlated with IFN‐β and ISG56 levels. HIV‐1‐infected males with enhanced IFN‐I levels and stenosis displayed a higher ASCVD calculated risk (p = .011) and D:A:D score (p = .004). Also, there was a trend toward higher IFN‐α and ISG56 mRNA levels in HIV‐1‐positive patients with an increased cIMT (p > .05). Dysregulation of IFN‐I response might participate in the pathogenesis of HIV‐1‐associated CVD.
This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second dose (T2), and more than 1 year later (T3). Anti‐S Abs were assessed by chemiluminescence and vesicular stomatitis virus (VSV)‐based pseudo virus‐neutralization assay, while IFN‐α2, IFN‐β, and IFN‐ω mRNA levels were measured by RT‐Real Time PCR. PLWH showed an increase in anti‐S Immunoglobulin G (IgG) levels comparable to healthy donors ( p < 0.001) and an induction of anti‐S neutralizing Abs ( p < 0.014 for T2 vs. T3). Age, gender, CD4 + T cell count, exposure to combined antiretroviral therapy (cART) and IFN‐I levels at T0 did not affect the anti‐S IgG production. IFN‐I gene expression showed temporal changes, with a decrease at T2 ( p < 0.01) and a subsequent increase at T3 ( p < 0.001, for IFN‐α2 and IFN‐ω). A multivariable model revealed no overall change in the IFN‐I response over time, except for IFN‐β, which was lower at T3 than at T1 ( p = 0.032). CD4 + T cell count was positively correlated with the IFN‐I response ( p < 0.05). These results suggest that mRNA vaccination can elicit an effective anti‐S response and modulate the IFN‐β gene expression in PLWH, with CD4 + T cell count being a key determinant of vaccine‐induced changes in IFN.